Titlebook: Stem Cell Surgery Trials in Heart Failure and Diabetes; A Concise Guide Jeffrey N. Weiss Book 2022 The Editor(s) (if applicable) and The Au

CAB

ICMNC-HF: IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patientsinfusion of autologous bone marrow mononuclear cells is safe and effective in heart failure patients with reduced left ventricular ejection fraction (<=30%) when compared with a control group comprising of patients undergoing the best medical care.

MILL

entail

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment oThe primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment of chronic heart failure due to LV systolic dysfunction.

浮夸

Allogeneic Stem Cell Therapy in Heart FailureThe present aim is to perform a clinical double-blind, placebo-controlled Cardiology Stem Cell Center – Adipose Stem Cells (CSCC_ASC) study in heart failure patients to investigate the regenerative capacity of the CSCC_ASC treatment.

離開真充足

Stem Cell Therapy in Ischemic Non-treatable Cardiac DiseaseThe aim of the SCIENCE study, an international multicenter, double-blind, placebo-controlled study, is to investigate the efficacy of direct intra-myocardial injection of 100 mio. allogeneic Cardiology Stem Cell Center adipose-derived stem cells (CSCC_ASCs) in patients with reduced left ventricular ejection fraction (EF) (≤45%) and heart failure.

Bravura

Cell Therapy in HFpEFThe primary objective of the study is to investigate the safety and efficacy of transendocardial CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and function, myocardial perfusion and electrical activity, biomarkers of neurohormonal activation, patient exercise capacity, and clinical outcome.

glamor

Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-DeSingle or repeated application of autologous bone marrow-derived stem cells to treat chronic post-infarction heart failure

去世

Stem Cell Therapy in Non-ischemic, Non-treatable Dilated Cardiomyopathies II: A Pilot StudyThe overall aim of the project is to test the feasibility and safety of allogeneic adipose-derived stromal cell (CSCC_ASC) investigational medicinal product to improve myocardial function in patients with non-ischemic dilated cardiomyopathies (NIDCM) and heart failure.

憲法沒(méi)有

Jeffrey N. WeissFunctions as a resource for new treatments for patients with heart failure and diabetes mellitus.Offers comprehensive information for physicians interested in stem cell technology.Provides a template

moratorium